Ocular Therapeutix (OCUL) EPS (Weighted Average and Diluted) (2018 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly EPS (Weighted Average and Diluted) of -$0.4 in Q1 2026, down 48.15% quarter-over-quarter from -$0.27 in Q4 2025, and down 5.26% on a YoY basis from -$0.42 in Q1 2025.
Ocular Therapeutix (OCUL) EPS (Weighted Average and Diluted) (2018 - 2026) Analysis & Trends
Ocular Therapeutix's EPS (Weighted Average and Diluted) history runs 9 years deep, the most recent figure standing at -$0.4 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 5.26% year-over-year to -$0.4; the TTM figure through Mar 2026 stood at -$1.44 (down 26.32% YoY), while the FY2025 annual figure was -$1.42, down 16.39% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.4 for Q1 2026 at Ocular Therapeutix, down from -$0.27 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.22 in Q1 2022 to a low of -$0.49 in Q1 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.31 across 5 years, with a median of -$0.27 in 2025.
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) tumbled 77.27% in 2023, then advanced 22.45% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.24 in 2022, then retreated by 4.17% to -$0.25 in 2023, then declined by 12.0% to -$0.28 in 2024, then advanced by 3.57% to -$0.27 in 2025, then tumbled by 48.15% to -$0.4 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.4 (Q1 2026), -$0.27 (Q4 2025), and -$0.38 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | -0.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.40 |
| Dec 31, 2025 | -0.27 |
| Sep 30, 2025 | -0.38 |
| Jun 30, 2025 | -0.39 |
| Mar 31, 2025 | -0.38 |
| Dec 31, 2024 | -0.28 |
| Sep 30, 2024 | -0.22 |
| Jun 30, 2024 | -0.26 |
| Mar 31, 2024 | -0.49 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -0.25 |
| Jun 30, 2023 | -0.26 |
| Mar 31, 2023 | -0.39 |
| Dec 31, 2022 | -0.24 |
| Sep 30, 2022 | -0.31 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.22 |
| Dec 31, 2021 | -0.23 |
| Sep 30, 2021 | -0.23 |
| Jun 30, 2021 | -0.25 |